BNP Paribas Financial Markets
TCRX icon

BNP Paribas Financial Markets’s TScan Therapeutics TCRX Stock Holding History

BNP Paribas Financial Markets’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$699 Hold
713
– – ﹤0.01% 5641
2026
Q1 		$720 Sell
713
-25,647
-97% -$27.4K ﹤0.01% 5503
2025
Q4 		$26.4K Sell
26,360
-3,510
-12% -$5.08K ﹤0.01% 4945
2025
Q3 		$54.4K Buy
29,870
+6,173
+26% +$10.9K ﹤0.01% 4568
2025
Q2 		$34.4K Sell
23,697
-28,144
-54% -$40.7K ﹤0.01% 4388
2025
Q1 		$71.5K Sell
51,841
-13,298
-20% -$28.8K ﹤0.01% 4161
2024
Q4 		$198K Buy
+65,139
New +$295K ﹤0.01% 3870

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return

BNP Paribas Financial Markets's TCRX Position: Q2 2026 in Review

BNP Paribas Financial Markets held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 713 shares worth $699. The position accounts for ﹤0.01% of the portfolio, ranked #5641.

BNP Paribas Financial Markets first reported a position in TCRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $198K in Q4 2024. 51 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • BNP Paribas Financial Markets held 713 shares of TScan Therapeutics worth $699 as of Q2 2026.
  • BNP Paribas Financial Markets left its TScan Therapeutics share count unchanged in Q2 2026.
  • TScan Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5641 holding.
  • BNP Paribas Financial Markets first reported a position in TScan Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's TScan Therapeutics position peaked at $198K in Q4 2024.
  • 51 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.